JanOne Inc. Banner Image

JanOne Inc. has reached its limit for free report views

Work for JanOne Inc.? Upgrade Your Profile and unlock all your annual reports.

JanOne Inc.

  • Ticker JAN
    Exchange NASDAQ More
  • Industry Waste Management More
  • Sector Industrial Goods More
JanOne Inc. Logo Image
  • 51-200 Employees
  • Based in Las Vegas, Nevada
JanOne (NASDAQ: JAN) is focused on developing treatments for diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The company is also exploring solutions for non-addictive pain medications. Its lead candidate JAN101 is for treating peripheral artery diseaseMore (PAD), a condition that affects over 8.5 million Americans. JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase 2b trials are expected to begin in early 2021. JanOne is dedicated to funding resources toward innovation, technology, and education for PAD, associated vascular conditions and neuropathic pain. JanOne continues to operate its legacy businesses under their current brand names, which are undergoing review to determine appropriate strategic alternatives.
4.8 / 5.0 (190)

JanOne Inc. reports have an aggregate usefulness score of 4.8 based on 190 reviews.

JanOne Inc.

Most Recent Annual Report

JanOne Inc.
MOST RECENT 2022 Annual Report and Form 10K

Report Locked. JanOne Inc. has reached its limit for free report views.

Older/Archived Annual Reports

JanOne Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!